Eikon Therapeutics: $3.25B valuation, IPO Readiness 54, Series A. Drug discovery company using real-time single-molecule microscopy to unlock previously undruggable targets. Track live on The IPO Stack.
Drug discovery company using real-time single-molecule microscopy to unlock previously undruggable targets.
Scores, valuations, and IPO signals for the companies that matter. 5-minute read, every Tuesday.
Top companies most likely to IPO in 2026, ranked by IPO Readiness Score.
Track Eikon Therapeutics IPO timeline, funding rounds, investor activity, and valuation on TechStackIPO — the pre-IPO intelligence platform.
Eikon Therapeutics has not publicly announced IPO plans. Track TechStackIPO for the latest signals and subscribe to The IPO Stack for weekly updates.
Eikon Therapeutics is valued at $3.25B as of March 2021. This valuation is based on its most recent private funding round tracked by TechStackIPO.
Accredited investors can access Eikon Therapeutics shares through secondary market platforms, pre-IPO investment funds, and broker-dealer platforms that facilitate private company transactions. TechStackIPO's marketplace tracks available access options. Note: pre-IPO investments carry higher risk and limited liquidity compared to public market investing.
Eikon Therapeutics scores 54/100 (Grade: D) on TechStackIPO's IPO Readiness Index. The score evaluates funding scale, valuation trajectory, funding momentum, stage progression, and company maturity. Scores above 70 indicate strong near-term IPO potential.
Eikon Therapeutics has raised $771M in total venture capital and private equity funding, with backing from Foresite Capital, a16z Bio, GV.
Eikon Therapeutics's notable investors include Foresite Capital, a16z Bio, GV, Andreessen Horowitz. Full investor details, funding round history, and lead investor breakdowns are available on TechStackIPO.
Eikon Therapeutics is a Biotechnology company. Drug discovery company using real-time single-molecule microscopy to unlock previously undruggable targets.